Mycobacterium tuberculosis-specific T cell responses are impaired during late pregnancy with elevated biomarkers of tuberculosis risk postpartum

2 3

1

<u>Authors</u>: Aparajita Saha^{1,2}, Jaclyn Escuduero², Troy Layouni³, Barbra Richardson^{2,4}, Sharon
 Hou², Nelly Mugo⁵, Andrew Mujugira^{2,6}, Connie Celum^{1,2,7}, Jared M. Baeten^{2,8} Jairam
 Lingappa^{1,2,4}, Grace C. John-Stewart^{1,2,7,9}, Sylvia M. LaCourse^{1,2*}, Javeed A. Shah^{1,2,3*}.

- 7 *Both authors contributed equally
- 89 Affiliations:
- ¹ Department of Medicine, University of Washington
- ² Department of Global Health, University of Washington
- 12 ³ VA Puget Sound Health Care System
- 13 ⁴ Department of Biostatistics, University of Washington
- ⁵ Kenya Medical Research Institute, Nairobi, Kenya
- 15 ⁶ Infectious Diseases Institute, Makerere University, Kampala, Uganda
- ⁷ Department of Pediatrics, University of Washington
- ⁸ Gilead Sciences, Foster City
- ⁹ Department of Epidemiology, University of Washington
- 19
- 20 <u>Corresponding author</u>: Javeed A. Shah, jashah@uw.edu; 206-543-8728
- 21

22 Author Contributions: AS: contributed to the design, data acquisition, analysis, and manuscript 23 preparation. JE: data analysis, manuscript preparation, sample collection and transport, TL: 24 statistical analysis, software, BR: data analysis, statistical support, manuscript editing; SH/HH: 25 sample transport, sample storage, database management, NM/AM: sample collection/storage, 26 participant enrollment, CC/JB: cohort enrollment, funding, sample storage, manuscript editing, 27 JL: cohort enrollment, sample storage, funding, manuscript editing, GJS: experimental design, data analysis, funding, manuscript editing, SL: experimental design, data analysis, grant 28 funding, manuscript preparation and editing; JAS: experimental design, data analysis, grant 29 30 funding, manuscript preparation and editing.

- 31 32 Grant Support: NICHD R21-HD098746, NIAID K23-AI120793, R01-AI136921,
- 33 Bill & Melinda Gates Foundation 26469, 41185, and 47674
- 34
- 35 <u>Short Title</u>: Pregnancy and Mtb T cell responses
- 36
- 37 <u>Descriptor</u>: 11.4 Mycobacterial Disease: Host Defenses
- 38

39 <u>Total Word Count</u>: 3534 40

41 This title has an online data supplement which is accessible from this issue's table of content

- 42 online at www.atsjournals.org.
- 43

44 Abstract

<u>Rationale:</u> Pregnancy is a risk factor for progression from latent tuberculosis infection (LTBI) to
 symptomatic tuberculosis (TB). However, how dynamic immunologic changes in pregnancy
 influence immune responses to *M. tuberculosis* (Mtb) is unknown.

48 <u>Objectives</u>: We performed a detailed characterization of Mtb-specific T cell responses of women 49 at high risk for Mtb infection, leveraging a biorepository of longitudinally samples collected 50 before, during, and after pregnancy in high HIV/TB burden settings.

<u>Methods:</u> We used specimens collected from women who became pregnant while enrolled in a randomized controlled trial of pre-exposure prophylaxis for HIV prevention. We measured Mtbspecific cytokines, CCR7 and CD45RA memory markers, and overall CD4+ and CD8+ T cell activation from 49 women using COMPASS, a Bayesian statistical method for evaluating overall antigen-specific T cell responses measured by flow cytometry.

56 Measurements and Main Results: 22 LTBI+ women, defined by flow cytometry, demonstrated 57 significantly diminished Mtb-specific CD4+ cytokine responses in the third trimester (COMPASS 58 score (PFS) 0.07) compared before (PFS 0.15), during (PFS 0.13 and 0.16), and after 59 pregnancy (PFS 0.14; p = 0.0084, Kruskal-Wallis test). Paradoxically, Mtb-specific CD8+ 60 cytokine responses and nonspecifically activated CD38+HLA-DR+CD4+ T cells increased 61 during late pregnancy. Nonspecific T cell activation, a previously validated biomarker for 62 progression from LTBI to TB disease, was increased in LTBI+ women postpartum, compared 63 with LTBI- women.

64 <u>Conclusions:</u> Pregnancy-related functional T cell changes were most pronounced during late 65 pregnancy. Mtb-specific T cell changes during pregnancy and postpartum, increases in immune 66 activation may contribute to increased risk for TB progression in the postpartum period.

67 Abstract Word Count: 245

68 Keywords: M. tuberculosis, pregnancy, T cells, T cell memory, T cell activation

69 Introduction

Tuberculosis (TB) disease in pregnancy and postpartum is associated with poor 70 71 maternal and infant outcomes (1, 2). Recent large cohort studies demonstrate that pregnancy is 72 associated with increased rates of tuberculosis disease (TB) up to six months postpartum (3, 4). 73 However, the immune mechanisms underpinning this observation are not clear. Successful 74 pregnancy requires dynamic alteration of the local immune environment (5-7). These 75 adaptations to fetal development are accompanied by cell-specific systemic immune alterations 76 (8). Pathogen-specific responses may be influenced by these systemic immune changes, which 77 can alter disease risk (9-11). Understanding pathogen-specific changes to the immune 78 response during pregnancy may improve efforts to prevent and control disease.

79

80 T cell responses are a critical aspect of Mtb host defense. Multiple lines of evidence, 81 including studies in mouse and nonhuman primate studies of CD4+ T cell knockout or depletion. 82 human genetic studies, and observational studies during HIV infection demonstrate that CD4+ T 83 cells are essential for Mtb control (12-16). Prior data suggests that IFNγ responses in CD4+ T 84 cells are essential for Mtb protection (17). The frequency of CD4+ T cells simultaneously 85 producing IL-2, TNF, and IFN γ (e.g., that are polyfunctional) is correlated with Mtb protection 86 (18). Other T cell phenotypes, such as central memory cells (Tcm) and CD8+ T cells, may 87 contribute to Mtb host defense (19-22). Conversely, increased total numbers of nonspecifically 88 activated HLA-DR+CD4+ T cells are a correlate of TB progression (23, 24). Since studies of 89 pregnancy commonly begin enrollment during the first or second trimester of pregnancy, they 90 are often unable to capture immune variation prior to and earlier in pregnancy. We leveraged a 91 unique biorepository of samples and data collected longitudinally before, during, and after 92 pregnancy from women in sub-Saharan Africa enrolled in a randomized controlled trial of preexposure prophylaxis for HIV prevention to evaluate the effects of various stages of pregnancy
on Mtb-specific T cell responses.

95

96 Methods

97 Study Population

98 The protocol for this study was approved by the University of Washington Human Subjects 99 Review Committee and ethics review committee at each study site. All participants provided 100 written informed consent in English or their native language. The Partners PrEP Study was a 101 randomized clinical trial of antiretroviral pre-exposure prophylaxis (PrEP) in HIV serodiscordant 102 couples (25). 4758 total participants were enrolled from 9 sites in Kenya and Uganda between 103 2007 and 2012. Partners with HIV and CD4 cell count >250, without history of AIDS-defining 104 diagnosis or current use of antiretroviral therapy (ART) were eligible. Participants without HIV 105 underwent monthly HIV testing from the parent trial and had urine pregnancy testing at 106 enrollment and monthly thereafter; women living with HIV (WLHIV) had urine collected quarterly. 107 WLHIV not already on ART who became pregnant were referred for prevention of maternal to 108 child transmission services. Participants were eligible for this analysis if they had at least two 109 samples available within 6 months prior to and during incident pregnancy. If available, additional 110 samples were tested from within 6 months postpartum. (Figure 1A). For participants with only 111 two timepoints available (before and during pregnancy), paired testing was done only on 112 participants with pregnancy samples from > 20 weeks gestation after interim evaluation of data 113 from participants with three time points samples. WLHIV received antiretrovirals for prevention 114 of maternal to child transmission of HIV, but not for treatment based on the guidelines at the 115 time.

116

117 Statistical Analysis

118 We used the R package COMPASS to analyze the overall cytokine response of CD4+ and 119 CD8+ T cells and to determine cytokine-producing subsets. COMPASS uses a Bayesian 120 hierarchical framework to model all observed cell subsets and select those most likely to have 121 antigen-specific responses (26, 27). COMPASS provided a functional score (FS), which is the 122 proportion of antigen specific subsets detected among all possible ones, and polyfunctional 123 score (PFS), which is similar, but weighs the different subsets to favor subsets with higher 124 degrees of functionality. Our primary outcome of interest was the COMPASS PFS from CD4+ 125 and CD8+ T cells of LTBI+ women with preexisting T cell responses against Mtb, restimulated 126 with pooled peptides from the Mtb-specific antigens ESAT-6 and CFP10. Differences in median 127 values were compared among timepoints of interest using Kruskal-Wallis tests as the primary 128 analysis, followed by Dunn's test to compare individual groups. Samples from women with and 129 without HIV were measured together except where indicated.

130

131 Results

132 Cohort characteristics and timing of sample collection

133 We identified 70 participants with incident pregnancy. 49 of these met criteria for this 134 study, with paired samples collected during pregnancy and another, collected less than 6 135 months prior to the pregnancy. 17 participants had samples collected from 3 timepoints (pre-, 136 during-, and post-pregnancy). 32 participants had samples collected before and during 137 pregnancy (Figure 1A). A total of 117 samples with evaluable results were analyzed; 48 pre-138 pregnancy (median 18.7 weeks [IQR 12.4-22.2), 47 during pregnancy, (median 26.9 weeks 139 gestation [IQR 12.7-30.9]); 22 post-partum (median 23.1 weeks [IQR 18.4-39.6]). The median 140 age of study participants was 26.4 years (IQR 23.2-31.1); 36.7% (18/49) were WLHIV with median CD4 766 cells/mm³ [IQR 507-1070]) (Table 1). 141

142

143 Identification of LTBI+ participants using flow cytometry

144 We identified individuals with LTBI using their first evaluable sample using a flow-based 145 assay as TST or IGRA were not performed during the original trial. We defined individuals as 146 LTBI+ if their proportion of the frequency of IFN γ +CD4+ T cells doubled after ESAT-6 and CFP-147 10 pooled peptide stimulation compared to DMSO. This measurement correlates well with 148 commercial IGRA tests (28-31). 22/49 (45%) individuals were LTBI+ by this measure (Figure 149 **1B**). We found that increasing the threshold for positivity to three-fold above background 150 reduced the proportion of LTBI+ individuals slightly, from 22 (44%) to 19 (41%). These 151 observations are similar in frequency to other studies of women of childbearing age in regions 152 with high Mtb burden (32). We used the initially identified more inclusive cutoff to ensure we 153 identified all individuals with pre-existing immune responses to Mtb. We identified three 154 individuals who were LTBI- at baseline but LTBI+ by their pregnancy visit. In these situations, 155 we included these individuals as LTBI+ from their first positive result onward.

156

157 CD4+ and CD8+ T cell frequency is consistent before, during, and after pregnancy

158 Our primary study objective was to identify the overall changes to the T cell response 159 using samples collected before, during, and after pregnancy among LTBI+ women. We first 160 identified the frequency of CD4+ and CD8+ T cells from samples collected before, during, and 161 after pregnancy (gating shown in **Figure S1A**). The frequency of CD4+ and CD8+ T cells was 162 similar over these time points (Figure 1B-C). In WLHIV, the frequency of CD4+ T cells was 163 lower than in women without HIV, irrespective of pregnancy status (Figure S1B) and CD8+ T 164 cell frequency was increased (Figure S1C). COMPASS FS and PFS of CD4+ T cells from all 165 samples strongly correlated with our LTBI measurements (Figure 1E-F).

166

167 *Mtb-specific CD4+ T cells polyfunctional responses decreased during the third trimester of* 168 *pregnancy* 169 Mtb induces a polyfunctional T cell response that may act independently of IFNy, and 170 these cells are critical for Mtb control (33). In Mtb-specific CD4+ T cells, PFS was significantly 171 different before, during, and after pregnancy (Figure 2A, gating in Figure S2; p = 0.0084, 172 Kruskal-Wallis test). PFS was significantly decreased in the third trimester compared with pre-173 pregnancy (p = 0.0005), second trimester (p = 0.0034) and post-pregnancy (p < 0.017), but not 174 during the first trimester (p = 0.099; Figure 2A). FS results were similar to PFS (Figure 2B). We 175 detected fewer Mtb-specific cytokine-producing subsets during third trimester, and very few 176 subsets producing multiple cytokines simultaneously (COMPASS heatmaps shown in Figure 177 **S3A**). We noted diminished single cytokine responses during the third trimester in IL-2+CD4+ 178 cells compared with the second trimester (Figure S3B; p = 0.026) which trended lower 179 compared with pre-pregnancy (p = 0.13), first trimester (p = 0.12) and post-pregnancy (p = 0.13) 180 0.09). CD4+TNF+ or CD4+IFNγ+ responses were similar across pregnancy (Figure S3C-D). 181 Therefore, using COMPASS, we were able to detect changes to Mtb-specific T cell responses 182 that may be clinically important but not immediately detectable by analyzing single cytokines 183 separately.

184

185 CD4+ T cell responsiveness to a mitogen is altered during the third trimester

186 Clinical laboratory tests for LTBI include mitogen controls to assess overall T cell 187 reactivity; impacts to mitogen induced CD4+ and CD8+ T cell responses during pregnancy 188 directly alter LTBI diagnostic test performance (34). We compared T cell responses after 189 stimulation with phorbol 12-myristate 13-acetate and ionomycin (PMA/ionomycin) over 190 pregnancy in all study participants. We evaluated these T cell responses using traditional flow 191 cytometry analysis, not COMPASS, as COMPASS is designed to detect antigen specific 192 responses observed at low frequency. The frequency of IL2+CD4+ T cells responding to 193 PMA/ionomycin were significantly changed over the duration of pregnancy (Figure 3A, p

194 <0.0001, Kruskal-Wallis test). IL-2+CD4+ responses in the third trimester were increased 195 compared to pre-pregnancy (p = 0.022), first trimester (p = 0.0006) and post-pregnancy (p < 0.022) 196 0.0001). TNF+CD4+ responses were also significantly increased during the third trimester 197 compared to first trimester (p = 0.0073) and post-pregnancy (p = 0.0002; Figure 3B, p = 0.0011198 overall). IFN γ +CD4+ cells decreased across pregnancy (p = 0.0036). The third trimester 199 response was significantly diminished compared to pre-pregnancy (p = 0.016), first trimester (p 200 = 0.026), second trimester (p = 0.049), and post-pregnancy (Figure 3C; p = 0.0001). IL-2+, 201 TNF+, and IFN γ + CD4+ T cell frequencies were each significantly different before and after 202 pregnancy (p = 0.006, p = 0.008, and p = 0.04, respectively), suggesting that systemic immune 203 alterations of pregnancy begin during the first trimester and persist for weeks to months after 204 birth. These data demonstrate distinct patterns of CD4+ T cell activation across pregnancy as 205 compared to Mtb-specific T cells.

206

207 *Mtb-specific CD8+ T cells increase in activity during the second and third trimester of pregnancy*

208 CD8+ T cells contribute to Mtb host defense and are measured in LTBI diagnostic tests 209 (35, 36), but little is known about how pregnancy impacts Mtb-specific CD8+ T cell responses. 210 We found low but detectable Mtb-specific CD8+ T cell cytokine responses in most samples from 211 LTBI+ participants (Figure S2, gating strategy). The PFS and FS in CD8+ T cells changed 212 significantly over the course of pregnancy (Figure 4A-B; p = 0.0033 and p = 0.038 respectively, 213 Kruskal-Wallis test). Median PFS in CD8+ T cells was nearly undetectable before pregnancy 214 and significantly increased in the second trimester compared with pre-pregnancy (p = 0.015), 215 the first trimester (p = 0.023), and post-pregnancy (p = 0.034). A similar trend was observed in 216 FS. The complexity of the CD8+ T cell response increased during the second and third 217 trimester, and we detected subsets producing multiple cytokines simultaneously (Figure S4A). 218 We were unable to detect shifts in IL-2, TNF, and IFN γ + CD8+ T cell responses when evaluated

singly, but we found a trend toward increased responses in each cytokine during the second and third trimester (**Figure S4B-D**). Taken together, Mtb-specific CD8+ T cell responses increased during the second and third trimester, while Mtb-specific CD4+ T cell responses diminished during the same period.

223

224 Mitogen-induced TNF+ CD8+ T cell responses increase during pregnancy

225 We measured the changes in PMA/ionomycin-stimulated CD8+ T cell responses over 226 the course of pregnancy in all participants. IL-2+CD8+ responses were unchanged by 227 pregnancy trimester (Figure 5D; p = 0.14, Kruskal-Wallis test). TNF+CD8+ T cell frequency 228 changed over the course of pregnancy (Figure 5E; p = 0.0084) and increased in the third 229 trimester compared with the first trimester (p = 0.015) and post-pregnancy (p = 0.0018). 230 IFNγ+CD8+ T cell frequencies were similar across pregnancy (Figure 5F). These responses 231 were distinct from the changes observed in Mtb-specific CD8+ T cells, where multiple subsets 232 increased in frequency during the second and third trimester.

233

234 Mtb-specific effector memory T cell populations diminish during the third trimester

235 T cells display cell surface markers CD45RA and CCR7 as markers of T cell memory 236 phenotype (37). Naïve (CCR7+CD45RA+), central memory (Tcm; CCR7+CD45RA-), and 237 effector memory (Tem; CCR7-CD45RA-) T cells display distinct functional profiles and tissue 238 homing sites, and Tcm are important for Mtb control (38-40). Naïve and Tcm produce little IFNy, 239 but Tem does not provide extended protection against disease. The frequency of total CD4+ 240 and CD8+ T cells expressing CD45RA and CCR7 did not change over pregnancy (Figure S5A-241 C). We evaluated CD45RA and CCR7 expression in Mtb-specific CD4+ T cells, which were 242 ESAT-6 and CFP-10 peptide incubated, cytokine-producing, CD4+ T cells from LTBI+ 243 individuals. The proportion of Mtb-specific naïve and Tcm CD4+ T cells remained stable (Figure 244 **6A-B**), but we observed reduced Tem frequency during the third trimester (Figure 6C, p =245 0.037; Kruskal-Wallis test) compared to pre-pregnancy (p = 0.049), first trimester (p = 0.005), 246 second trimester (p = 0.014), and postpartum (p = 0.031). Viewed proportionally, naïve CD4+ 247 cells increased while Tem decreased during the third trimester of pregnancy compared to the 248 first trimester, second trimester, and postpartum, without substantial changes to Tcm frequency 249 (Figure 6D). We did not detect adequate Mtb-specific CD8+ T cells to evaluate T cell 250 phenotypes in this population. In sum, Tem and IFN_γ+CD4+ cells were reduced during the third 251 trimester, but without increases in the Tcm population, which is important for Mtb host defense 252 and may predict worsened Mtb control.

253

254 Nonspecific T cell activation increases during pregnancy

255 Increased nonspecific CD4+ T cell activation is a correlate of risk for developing Mtb 256 disease (41, 42). We measured the frequency of HLA-DR+CD38+ CD4+ and CD8+ T cells 257 across pregnancy, using "flow minus one" controls (Figure S6A). The frequency of HLA-DR+CD38+ CD4+ T cells significantly changed over pregnancy (Figure 7A; p < 0.0001, 258 259 Kruskal-Wallis test), highest in the third trimester compared to pre-pregnancy (p = 0.0068), first 260 trimester (p < 0.0001), second trimester (p = 0.007), or postpartum (**Figure 7A**; p < 0.0001). 261 HLA-DR+CD38+ CD8+ T cell frequency also significantly changed similarly to CD4+ T cells 262 (Figure 7B; p < 0.0001, Kruskal-Wallis test). In both CD4+ and CD8+ T cells, activation markers 263 decreased from pre-pregnancy to the first trimester, and WLHIV demonstrated the greatest T 264 cell activation throughout pregnancy. Therefore, T cell activation decreases at the outset of 265 pregnancy, then increases over time until delivery.

We leveraged the observation that CD4+ T cell activation is a biomarker for TB risk to evaluate if the immune changes of pregnancy might increase the risk for TB progression from asymptomatic to symptomatic disease. We hypothesized that selective increases in nonspecific T cell activation would be present in LTBI+ women after pregnancy due to their increased risk for postpartum Mtb progression but not for LTBI- women. Pre-pregnancy, the proportion of HLADR+CD38+CD4+ T cells was equivalent between LTBI- and LTBI+ individuals (**Figure 7C**). Postpartum, LTBI+ individuals demonstrated significantly higher HLA-DR+CD38+ CD4+ T cells as compared to LTBI- individuals (**Figure 7D**; p = 0.0026, Mann-Whitney test). Immune changes of pregnancy in LTBI+ individuals may substantially contribute to overall T cell activation in the postpartum period and predict increased risk for TB progression.

276

277 Discussion

278 In this study, we performed a comprehensive analysis of pregnancy stage on Mtb-279 specific T cell phenotypes in sub-Saharan African women including women living with HIV. 280 These data are, to our knowledge, the first longitudinal assessment of systemic T cell responses 281 to Mtb in pregnancy that includes samples collected prior to pregnancy. Taken in sum, we found 282 that late pregnancy is associated with multiple changes to Mtb-specific T cell function: 1) overall 283 Mtb-specific CD4+ T cell responses diminished and simplified; 2) Mtb-specific CD4+ Tem, which 284 are cells that strongly produce IFNy, decreased (37); 3) Mtb-specific CD8+ T cell responses 285 increased, and 4) nonspecific T cell activation increased. (Figure 8). Nonspecific T cell 286 activation increased in LTBI+ individuals compared to LTBI- individuals postpartum, despite 287 being equivalent pre-pregnancy. Increased nonspecific T cell activation, a correlate of risk for 288 Mtb disease in LTBI+ individuals, supports the observation that TB risk increases in the early 289 postpartum period (41). Together, late pregnancy induces complex changes in the known T cell 290 response to Mtb that have been associated with TB progression in other populations, and we 291 found that LTBI+ women develop increased correlates of risk for TB in the immediate 292 postpartum period.

293

294 We observed distinct changes between Mtb-specific and more generalized mitogen 295 (PMA/ionomycin)-induced T cell cytokine responses. These results have direct implications 296 toward the performance of LTBI diagnostics in pregnant women. Mtb-specific CD4+ T cell 297 responses decreased during the third trimester but increased in the second trimester, and Mtb-298 specific CD8+ T cell responses were low but increased during the second and third trimester. 299 By contrast, overall mitogen responses in CD4+ T cells, especially IL-2 responses, increased 300 during late pregnancy. In other cohorts, discordance between the two commonest LTBI tests, 301 TST and IGRA, has been noted especially among women in the late second and early third 302 trimester, which may be partly due to the changes in the immune responses of pregnancy (34, 303 43). Part of the difference may be due to the absence of mitogen testing in most TSTs. 304 Understanding this discordance in pregnancy may have implications for TB progression. Among 305 those with positive IGRA but negative TST tests, Mtb-specific IL-2 responses associated with 306 postpartum TB progression from asymptomatic infection to symptomatic disease (44). In 307 combination, discordance between Mtb-specific and nonspecific immune responses may 308 contribute to increased false-negative LTBI testing during the third trimester and may contribute 309 to Mtb progression.

310

311 Conversely, we found that Mtb-specific CD8+ T cell responses increased during late 312 pregnancy when CD4+ T cell responses were diminished. The role of CD8+ T cells in TB 313 pathogenesis is uncertain. In children, Mtb-specific CD8+ T cell frequencies are correlated with 314 Mtb disease (45). In animals, CD8+ T cell responses correlate strongly with Mtb bacterial 315 burden in the lung (46, 47). CD8+ T cells recognize antigens presented on major 316 histocompatibility complex I, which presents intracellular antigens. CD8+ T cells preferentially 317 recognize antigen-presenting cells with an increased bacterial burden (48). During active 318 intracellular infection, these responses may increase proportionally. It is unclear if some of these 319 responses reflect emerging TB disease or if there are general postpartum factors that enhance 320 CD8+ responses. These data suggest that CD8+ T cell responses may increase to compensate

for diminished CD4+ T cell responses but may be unable to fully reproduce CD4+ T cell immune
 control.

323

324 The strengths of this study include its longitudinal nature, including samples obtained 325 before, during, and after pregnancy. Most studies of the effects of pregnancy enroll women 326 during pregnancy and often focus on the second and third trimester, which do not capture pre-327 pregnancy and first trimester periods. Several T cell phenotypes change significantly between 328 pre-pregnancy and the first trimester, and other phenotypes differed between pre-pregnancy 329 and postpartum. Local inflammation is critical for embryonic implantation, which suggests that 330 both local and systemic immune changes begin immediately and are prolonged post-partum 331 (49, 50). Another strength of this study was the use of COMPASS. COMPASS analysis 332 revealed two findings that were not observable using standard data analysis techniques. This 333 sensitive analysis permitted us to observe the diminished complexity of the Mtb-specific CD4+ T 334 cell response during the third trimester and increases in overall CD8+ activity. Taken together, 335 no single cytokine response accounted for the changes to the Mtb-specific T cell response, 336 suggesting broad changes in the functional capacity of T cells responding to antigen during the 337 third trimester.

338

339 Weaknesses of this study include the lack of TB disease outcomes data. This study 340 used repository samples from a trial not originally designed to evaluate TB. However, we 341 performed detailed immune characterization of the changes to the Mtb-specific immune 342 response across pregnancy. Importantly, LTBI+ women had increased T cell activation 343 postpartum, when compared with LTBI- women, which is a validated biomarker of TB disease 344 progression in other cohorts (23). IGRA or TST was not performed in the parent study, which 345 prevents correlation with clinically validated LTBI testing. However, the method we used in this 346 study to identify LTBI+ participants is a well-accepted alternate approach that correlates with

347 LTBI diagnosis (30, 31). Generally, flow-based testing is more sensitive to detect prior exposure 348 to Mtb antigens than IGRA, so this approach permits us to evaluate a broader range of 349 individual immune responses. Errors introduced by the inclusion of individuals without 350 preexisting Mtb exposures are likely to reduce the sensitivity of this analysis to detect changes. 351 We performed sensitivity analyses by raising the threshold for LTBI+ identification, but this did 352 not substantially change the number of participants considered to have LTBI. Due to the limited 353 sample size of this study, we did not perform formal analysis to investigate the impact of HIV on 354 immune responses during pregnancy. Although HIV status was associated with reduced CD4+ 355 T cell count and increased T cell activation, we found immune changes of pregnancy were 356 generally independent of HIV status, though direct comparisons were limited due to small 357 sample size.

358

359 TB is the third leading cause of death among women of child-bearing age in high burden 360 areas and is associated with morbidity and mortality in pregnant women and their children, 361 especially among those affected by HIV (1, 43). Our study provides evidence that systemic 362 changes in the T cell response during the third trimester may contribute to increased risk for TB 363 progression. T cell cytokine responses are reduced and simplified, T cell memory phenotypes 364 skewed toward naïve phenotypes, and nonspecific activation is enhanced, which all are 365 independently associated with TB risk. Recent data suggest that isoniazid preventative therapy 366 is associated with adverse pregnancy outcomes, with a signal that this may occur more often if 367 initiated early in pregnancy (51). As such, late pregnancy, which is associated with key 368 immunologic changes for TB progression, may be an advantageous time to target for shorter 369 course regimens. Understanding host factors that place pregnant mothers at risk for TB may 370 provide insight into optimal public health strategies for TB control in this high-risk population.

371

372 Acknowledgements

373 The authors would like to thank the study participants and their families. We would like to 374 acknowledge the support of Harald Haugen on database management of clinical samples. We 375 would also like to acknowledge the clinical teams who obtained informed consent and collected 376 samples for this biorepository. We would also like to thank Chetan Seshadri for helpful technical 377 conversations.

378 Figure Legends

- 379 Figure 1. Baseline Immune Characteristics Are Stable Across Pregnancy.
- A) Flowchart of stored sample selection of participants with incidental pregnancies in thePartners PrEP study.
- B) Proportion of CD4+ T cells of all CD3+ cells, by pregnancy, trimester, and HIV status. Here
- 383 and throughout, Samples indicated with *black circles* are from HIV- donors, while *gold triangles*
- are from WLHIV here and throughout this study.
- 385 C) Proportion of CD8+ T cells, stratified by pregnancy, trimester, and HIV status.

Pre-pregnancy sample N = 49; 1st trimester N = 9, 2nd trimester N = 14; 3rd trimester N = 24; postpartum N = 22. *Black circles* indicate HIV- study participants, while *gold tria*ngles indicate WLHIV here and throughout this paper. Bars indicate median values. Statistical difference between CD4 and CD8+ T cells was measured by Kruskal-Wallis test with sub-analysis comparing column medians.

- 391 D) Fold change of the proportion of CD4+ T cells expressing IFNγ after incubation with ESAT-6
- and CFP-10 pooled peptides, compared to vehicle control.
- 393 E) COMPASS functional score (FS), stratified by LTBI status.
- 394 F) COMPASS polyfunctional score (PFS), stratified by LTBI status.
- 395

Figure 2. Mtb-specific CD4+ T cell responses are diminished during the third trimester of
 pregnancy.

- 398 A) Polyfunctional scores (PFS) generated from COMPASS analysis, stratified by pregnancy
- 399 trimester. *Black dots* indicate an HIV- study participant, while gold triangles indicate a WLHIV.
- 400 Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-
- 401 to-column comparisons are made with Dunn's test.
- 402 B) Functional scores (FS) generated from COMPASS analysis, stratified by pregnancy 403 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.

Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-
to-column comparisons are made with Dunn's test.

406

Figure 3. PMA/ionomycin-stimulated CD4+ T cell cytokine responses are dynamic across
pregnancy.

409 A-C) Proportion of A) IL-2+CD4+, B) TNF+CD4+, or C) IFN γ +CD4+ T cells, stratified by 410 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a 411 WLHIV. Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, GEE with estimating 412 equation, connected by *overhead bar*.

413 D-F) Proportion of D) IL-2+CD4+, E) TNF+CD4+, or F) IFN γ +CD4+ T cells, stratified by 414 pregnancy trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate 415 an HIV+ study participant. Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, 416 Overall significant by Kruskal-Wallis test demonstrated with top, *thick line without overhangs*. 417 Column-to-column comparisons are made with Dunn's test and shown with *thinner bars with* 418 *overhangs*.

419

420 Figure 4. Mtb-specific CD8+ T cell polyfunctionality increases during the second 421 trimester of pregnancy.

A) Polyfunctional scores (PFS) generated from COMPASS analysis, stratified by pregnancy
trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.
Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-
to-column comparisons are made with Dunn's test. *Black dots* indicate an HIV- study
participant, while *gold triangles* indicate a sample from WLHIV study participant.

B) Functional scores (FS) generated from COMPASS analysis, stratified by pregnancy
trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.

- Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-
 to-column comparisons are made with Dunn's test.
- 431

432 Figure 5. Cytokine responses in PMA/ionomycin-stimulated CD8+ T cells are stable 433 during pregnancy.

434 A-C) Proportion of A) IL-2+CD8+, B) TNF+CD8+, or C) IFN γ +CD8+ T cells, stratified by 435 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate an 436 HIV+ study participant. Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, GEE 437 with estimating equation, connected by *overhead bar*.

438 D-F) Proportion of D) IL-2+CD8+, E) TNF+CD8+, or F) IFN γ +CD8+ T cells, stratified by 439 pregnancy trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate 440 an HIV+ study participant. Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, 441 Kruskal-Wallis test. Column-to-column comparisons are made with Dunn's test.

442

Figure 6. Proportions of Mtb-specific naïve CD4+ T cells increase and effector memory T cells decrease during the third trimester of pregnancy.

445 A-C) Overall proportion of A) naïve (CCR7+CD45RA+), B) central memory (T_{CM} ; 446 CCR7+CD45RA-), and C) effector memory (T_{EM} ; CCR7-CD45RA-) among all cytokine-447 producing CD4+ T cells after re-stimulation with ESAT-6 and CFP-10 antigens, stratified by 448 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a 449 sample from WLHIV study participant. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. 450 Column-to-column comparisons are made with Dunn's test.

D) Pie chart of Boolean-gated T helper memory phenotype frequencies, comparing the third
trimester with other timepoints, connected by *overhead bar*. *Blue* arc indicates CCR7+ cells, *red*arc indicates CD45RA+ cells. *Red* pie slice: Naïve CD4+ T cells (Naïve); *blue* pie slice: effector

454 memory CD4+ T cells (Tem); *gray* slice: central memory T cell (Tcm); *white* slice: TEMRA cell
455 (TEMRA). * P < 0.05, ** P < 0.01, *** P < 0.001, permutation test of 10000 iterations.

456

Figure 7. Nonspecific T cell activation increases during pregnancy and LTBI+ women
 demonstrate increased T cell activation postpartum

459 A) Proportion of HLA-DR+CD38+ CD4+ T cells, stratified by pregnancy status.

B) Proportion of HLA-DR+CD38+ CD8+ T cells, stratified by pregnancy status.

461 C) Proportion of HLA-DR+CD38+ CD4+ T cells from samples collected pre-pregnancy, stratified

462 by LTBI status of the participant.

463 D) Proportion of HLA-DR+CD38+ CD4+ T cells from samples collected postpartum, stratified by 464 LTBI status of the participant. *Black dots* indicate an HIV- study participant, while *gold triangles* 465 indicate sample from WLHIV. Thick bars correspond to overall changes (Krukal-Wallis test). 466 *Bars with overhangs* indicate analysis of differences between columns (Dunn's test). Bars 467 indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-to-468 column comparisons are made with Dunn's test in multiple group comparisons or Mann-Whitney 469 U-test for tests between two groups.

470

Figure 8. Summary of overall Mtb-specific T cell responses during differing stages of pregnancy. We observed distinct changes in Mtb-specific T cell responses as compared to mitogen-stimulated T cells. Arrows indicate the overall frequency of the responses measured. A downward arrow followed by an upward arrow indicates diminished IL-2/TNF responses with simultaneous increases in IFN γ + cell frequency, and an upward arrow followed by a downward arrow indicates increases in IL-2/TNF+ T cell frequency with decreases in IFN γ + responses.

477	References
478 479	1. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women:
480	epidemiology, management, and research gaps. Clin Infect Dis 2012; 55: 1532-
481	1549.
482	2. Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered
483	questions for pregnant and postpartum women living with HIV: the need for
484	improved evidence. J Int AIDS Soc 2020; 23: e25481.
485	3. Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active
486	tuberculosis during pregnancy and postpartum: a register-based cohort study in
487	Sweden. <i>Eur Respir J</i> 2020; 55.
488	4. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy:
489	a national, primary care-based cohort and self-controlled case series study. $Am J$
490	Respir Crit Care Med 2012; 185: 779-784.
491	5. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of
492	pregnancy. Nat Rev Immunol 2017; 17: 469-482.
493	6. Erlebacher A. Immunology of the Maternal-Fetal Interface. Annual Review of
494	Immunology 2013; 31: 387-411.
495	7. Shah NM, Herasimtschuk AA, Boasso A, Benlahrech A, Fuchs D, Imami N, Johnson
496	MR. Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy
497	Are Indicative of a Shift from Immune Tolerance to Immune Activation. Front
498	Immunol 2017; 8: 1138.
499	8. Aghaeepour N, Ganio EA, McIlwain D, Tsai AS, Tingle M, Van Gassen S, Gaudilliere
500	DK, Baca Q, McNeil L, Okada R, Ghaemi MS, Furman D, Wong RJ, Winn VD,

501	Druzin ML, EI-Sayed YY, Quaintance C, Gibbs R, Darmstadt GL, Shaw GM,
502	Stevenson DK, Tibshirani R, Nolan GP, Lewis DB, Angst MS, Gaudilliere B. An
503	immune clock of human pregnancy. Sci Immunol 2017; 2.

- 504 9. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and Infection. *New England Journal* 505 of *Medicine* 2014; 370: 2211-2218.
- 506 10. Racicot K, Mor G. Risks associated with viral infections during pregnancy. *J Clin* 507 *Invest* 2017; 127: 1591-1599.
- 508 11. Kay AW, Fukuyama J, Aziz N, Dekker CL, Mackey S, Swan GE, Davis MM, Holmes
- 509 S, Blish CA. Enhanced natural killer-cell and T-cell responses to influenza A virus 510 during pregnancy. *Proc Natl Acad Sci U S A* 2014; 111: 14506-14511.
- 511 12. Leveton C, Barnass S, Champion B, Lucas S, De Souza B, Nicol M, Banerjee D,
 512 Rook G. T-cell-mediated protection of mice against virulent Mycobacterium
 513 tuberculosis. *Infection and immunity* 1989; 57: 390-395.
- 514 13. Sakai S, Mayer-Barber KD, Barber DL. Defining features of protective CD4 T cell
 515 responses to Mycobacterium tuberculosis. *Curr Opin Immunol* 2014; 29: 137 516 142.
- 517 14. Müller I, Cobbold S, Waldmann H, Kaufmann S. Impaired resistance to 518 Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ 519 and Lyt-2+ T cells. *Infection and immunity* 1987; 55: 2037-2041.
- 15. Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, Flynn JL. CD4 T cell
 depletion exacerbates acute Mycobacterium tuberculosis while reactivation of
 latent infection is dependent on severity of tissue depletion in cynomolgus
 macaques. *AIDS Res Hum Retroviruses* 2012; 28: 1693-1702.

- 524 16. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on
 525 incidence of tuberculosis in South Africa: a cohort study. *The Lancet* 2002; 359:
 526 2059-2064.
- 527 17. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL.
- 528 CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of Pulmonary 529 Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 530 to Prevent Lethal Disease. *PLoS Pathog* 2016; 12: e1005667.
- 531 18. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ.
 532 Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not
 533 spleen, correlate with protection against Mycobacterium tuberculosis aerosol
 534 challenge in mice. *The Journal of Immunology* 2008; 181: 4955-4964.
- 535 19. Lindenstrom T, Knudsen NP, Agger EM, Andersen P. Control of chronic
 536 mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central
 537 memory cells. *J Immunol* 2013; 190: 6311-6319.
- 20. Andersen P, Urdahl KB. TB vaccines; promoting rapid and durable protection in the
 lung. *Curr Opin Immunol* 2015; 35: 55-62.
- 540 21. Grotzke JE, Lewinsohn DM. Role of CD8(+) T lymphocytes in control of 541 Mycobacterium tuberculosis infection. *Microbes and Infection* 2005; 7: 776-788.

542 22. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa

- 543 S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF,
- 544 Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA. CD8+
- 545 T cells provide an immunologic signature of tuberculosis in young children. Am J

546 *Resp Crit Care* 2012; 185: 206-212.

547 23. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M,
548 Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L,
549 Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,
550 Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H,
551 Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell
552 activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*553 2016; 7: 11290.

- Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM,
 Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and
 monitor treatment response. *J Clin Invest* 2015; 125: 1827-1838.
- 557 25. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, 558 Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesiqve E, Were E, Fife KH, Kiarie J, Farguhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-559 Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, 560 561 Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, 562 Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C. 563 564 Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. 565 New England Journal of Medicine 2012; 367: 399-410.
- Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M,
 Hoal EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR. A
 Functional TOLLIP Variant is Associated with BCG-Specific Immune Responses
 and Tuberculosis. *Am J Respir Crit Care Med* 2017.

27. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H,
Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal
J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ,
Karasavvas N, Gilbert P, S CDR, McElrath MJ, Gottardo R. COMPASS identifies
T-cell subsets correlated with clinical outcomes. *Nat Biotechnol* 2015; 33: 610616.

- 576 28. Tesfa L, Koch FW, Pankow W, Volk HD, Kern F. Confirmation of Mycobacterium
 577 tuberculosis infection by flow cytometry after ex vivo incubation of peripheral
 578 blood T cells with an ESAT-6-derived peptide pool. *Cytometry Part B: Clinical*579 *Cytometry: The Journal of the International Society for Analytical Cytology* 2004;
 580 60: 47-53.
- 29. Papageorgiou CV, Anastasopoulos A, Ploussi M, Leventopoulos M, Karabela S,
 Fotiadis K, Papavasileiou A, Vogiatzakis E, Ioakeimidis D, Gritzapis AD, Poulakis
 N. Flow cytometry analysis of CD4+IFN-gamma+ T-cells for the diagnosis of
 mycobacterium tuberculosis infection. *Cytometry B Clin Cytom* 2016; 90: 303311.
- 30. Lee J, Lee SY, Won DI, Cha SI, Park JY, Kim CH. Comparison of whole-blood
 interferon-gamma assay and flow cytometry for the detection of tuberculosis
 infection. *J Infect* 2013; 66: 338-345.
- 31. Sauzullo I, Scrivo R, Mengoni F, Ermocida A, Coppola M, Valesini G, Vullo V,
 Mastroianni CM. Multi-functional flow cytometry analysis of CD4+ T cells as an
 immune biomarker for latent tuberculosis status in patients treated with tumour
 necrosis factor (TNF) antagonists. *Clin Exp Immunol* 2014; 176: 410-417.

- 32. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women:
 Epidemiology, Management, and Research Gaps. *Clinical Infectious Diseases* 2012; 55: 1532-1549.
- 33. Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH,
 McKitrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR,
 Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G. IFN-γ-independent
 immune markers of Mycobacterium tuberculosis exposure. *Nat Med* 2019; 25:
 977-987.
- 34. LaCourse SM, Cranmer LM, Matemo D, Kinuthia J, Richardson BA, Horne DJ,
 John-Stewart G. Effect of Pregnancy on Interferon Gamma Release Assay and
 Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected
 Women in a High Burden Setting. *J Acquir Immune Defic Syndr* 2017; 75: 128136.
- 35. Lin PL, Flynn JL. CD8 T cells and Mycobacterium tuberculosis infection. *Semin Immunopathol* 2015; 37: 239-249.
- 36. Tsuyuzaki M, Igari H, Okada N, Suzuki K. Role of CD8 T-cell in immune response to
 tuberculosis-specific antigen in QuantiFERON-TB Gold Plus. *J Infect Chemother*2020; 26: 570-574.
- 37. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection:
 implications for vaccine design. Nat Rev Immunol; 2008. p. 247-258.
- 613 38. Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory.
 614 *Immunity* 2018; 48: 214-226.

- 39. Lindenstrøm T, Knudsen NPH, Agger EM, Andersen P. Control of chronic
 Mycobacterium tuberculosis infection by CD4 KLRG1– IL-2–secreting central
 memory cells. *The Journal of Immunology* 2013; 190: 6311-6319.
- 40. Vogelzang A, Perdomo C, Zedler U, Kuhlmann S, Hurwitz R, Gengenbacher M,
 Kaufmann SH. Central memory CD4+ T cells are responsible for the recombinant
 bacillus Calmette-Guerin Δ ureC:: hly vaccine's superior protection against
 tuberculosis. *The Journal of infectious diseases* 2014; 210: 1928-1937.
- 41. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M,
 Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L,
 Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,
 Darboe F, Penn-Nicholson A, Nemes E, Hatheril M, Hussey G, Mahomed H,
 Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell
 activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*2016; 7: 11290.
- 42. Arenas-Hernandez M, Romero R, Xu Y, Panaitescu B, Garcia-Flores V, Miller D,
 Ahn H, Done B, Hassan SS, Hsu CD, Tarca AL, Sanchez-Torres C, GomezLopez N. Effector and Activated T Cells Induce Preterm Labor and Birth That Is
 Prevented by Treatment with Progesterone. *J Immunol* 2019; 202: 2585-2608.
- 43. Mathad JS, Bhosale R, Sangar V, Mave V, Gupte N, Kanade S, Nangude A,
 Chopade K, Suryavanshi N, Deshpande P, Kulkarni V, Glesby MJ, Fitzgerald D,
 Bharadwaj R, Sambarey P, Gupta A. Pregnancy differentially impacts
 performance of latent tuberculosis diagnostics in a high-burden setting. *PLoS One* 2014; 9: e92308.

44. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N,
Gupte N, Joshi S, Chandanwale A, Dupnik KM, Kulkarni V, Deshpande P,
Fitzgerald DW, Gupta A. Quantitative IFN-gamma and IL-2 Response Associated
with Latent Tuberculosis Test Discordance in HIV-infected Pregnant Women. *Am J Respir Crit Care Med* 2016; 193: 1421-1428.

- 45. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa
 S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF,
 Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA, Unit
 TR. CD8+ T Cells Provide an Immunologic Signature of Tuberculosis in Young
 Children. *Am J Resp Crit Care* 2012; 185: 206-212.
- 46. Lewinsohn DM, Tydeman IS, Frieder M, Grotzke JE, Lines RA, Ahmed S, Prongay
 KD, Primack SL, Colgin LMA, Lewis AD, Lewinsohn DA. High resolution
 radiographic and fine immunologic definition of TB disease progression in the
 rhesus macaque. *Microbes and Infection* 2006; 8: 2587-2598.
- 47. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J. Induction of CD8 T Cells
 against a Novel Epitope in TB10.4: Correlation with Mycobacterial Virulence and
 the Presence of a Functional Region of Difference-1. *The Journal of Immunology*2007; 179: 3973-3981.
- 48. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM.
 Mycobacterium tuberculosis–specific CD8+ T Cells Preferentially Recognize
 Heavily Infected Cells. *Am J Resp Crit Care* 2003; 168: 1346-1352.

659	49.	Zenclussen	AC,	Hämmerling	GJ.	Cellular	Regulatior	of	the	Uteri	ne
660		Microenviro	nment	That Enables	Embr	yo Implan	ntation. Fror	nt Imr	nunol	2015;	6:
661		321.									

50. Gnainsky Y, Granot I, Aldo P, Barash A, Or Y, Mor G, Dekel N. Biopsy-induced inflammatory conditions improve endometrial receptivity: the mechanism of action. *Reproduction* 2015; 149: 75-85.

- 51. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T,
 Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A,
- 667 Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K,
- Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A,
- 669 Team IPTBAS. Isoniazid Preventive Therapy in HIV-Infected Pregnant and
- 670 Postpartum Women. *New England Journal of Medicine* 2019; 381: 1333-1346.

671

	Overall	LTBI+*	LTBI-	DD		
Characteristic	Median (IQR) or n (%)	Median (IQR) or n (%)	Median (IQR) or n (%)	(95% CI)	р	
Baseline	N=49**	N=19	N=30			
Age (years)	26.4 (23.2-31.3)	26.8 (23.2-31.1)	26.2 (22.7-31.5)	1.02 (0.94-1.10)	0.624	
WLHIV	18 (36.7)	6 (31.6)	12 (40.0)	0.79 (0.36-1.74)	0.565	
CD4 (cells/mm ³)	765.5 (507-1070)	868.5 (588-1272)	730.5 (476.5-1042)	1.00 (1.00-1.00)	0.258	
Samples	N=117	N=48	N=69			
Pregnancy stage				1.10 (0.83-1.47)	0.496	
Pre-pregnancy^	48 (41.0)	18 (37.5)	30 (43.5)			
Pregnancy	47 (40.2)	20 (41.7)	27 (39.1)	0.77 (0.52-1.14)	0.184	
1 st trimester (0 to <14 weeks)	9 (19.2)	5 (25.0)	4 (14.8)			
2 nd trimester (14 to <28 weeks)	14 (29.8)	7 (35.0)	7 (25.9)			
3 rd trimester (≥28 weeks)	24 (51.1)	8 (40.0)	16 (59.3)			
Post-pregnancy***	22 (18.8)	10 (20.8)	12 (17.4)			
Timing of sample collection (weeks)						
Pre-pregnancy	-18.7 (-22.2 – -12.4)	-18.3 (-22.3 – -11.7)	-18.8 (-22.1 – -13.1)	1.00 (0.96-1.03)	0.836	
During pregnancy	26.9 (12.7-30.9)	18.9 (11.7-28.1)	28.7 (22.4-32.0)	0.97 (0.94-1.00)	0.077	
Post-pregnancy	23.1 (18.4-39.6)	19.5 (17.3-45.6)	30.5 (21.4-38.7)	1.00 (0.97-1.03)	0.980	

672 Table 1. Baseline characteristics of participants and timing of samples with evaluable results

673 Abbreviations: WLHIV-People living with HIV, LTBI-Latent Tuberculosis Infection, RR-Relative Risk

674 * LTBI diagnosis determined by 2x increase of frequency of IFNg+CD4+ cells after stimulation with Mtb antigens over control

675 ** Includes one participant whose pre-pregnancy sample was unevaluable

676 *** Up to six months after delivery

677 [^] Samples collected up to six months before date of conception

678



Β

D









Figure 4







Pregnancy

Figure 7



	Pre- pregnancy	1 st Trimester	2 nd trimester	3 rd trimester	postpartum				
Mtb-specific T-cells									
CD4+	\longleftrightarrow	\leftrightarrow	\downarrow	$\downarrow \downarrow \downarrow$	\leftrightarrow				
CD8+	$\downarrow\downarrow\downarrow\downarrow$	$\downarrow\downarrow$	$\uparrow \uparrow$	1	$\downarrow\downarrow$				
Mitogen stimulated T-cells									
CD4+	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑↓	$\downarrow\uparrow$				
CD8+	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow				
Nonspecific T-cell activation									
Activated T- cells	\leftrightarrow	\downarrow	$\uparrow \uparrow$	$\uparrow \uparrow \uparrow$	1				